eli lilly phase 3 trial retatrutide obesity results 2026 Retatrutide produces up to 30.3%

Benefits include more consistent appetite suppression, fewer GI side effects, and better receptor engagement

When considering the science behind GLP-1s, this outcome aligns with expectations

Body composition: DEXA scan at baseline, 12 weeks, and 24 weeks minimum

It influences multiple systems simultaneously, some of which can decrease desire (dopamine suppression, serotonin changes, hormonal shifts) and some of which can increase desire (weight loss, improved body image, better cardiovascular health)

Koi Research Labs LLC is a chemical supplier, not a compounding pharmacy under 503A nor an outsourcing facility under 503B of the Federal Food, Drug, and Cosmetic Act

Introductory coupon pricing can help temporarily as well